Literature DB >> 11796612

Phase variation of Campylobacter jejuni 81-176 lipooligosaccharide affects ganglioside mimicry and invasiveness in vitro.

Patricia Guerry1, Christine M Szymanski, Martina M Prendergast, Thomas E Hickey, Cheryl P Ewing, Dawn L Pattarini, Anthony P Moran.   

Abstract

The outer cores of the lipooligosaccharides (LOS) of many strains of Campylobacter jejuni mimic human gangliosides in structure. A population of cells of C. jejuni strain 81-176 produced a mixture of LOS cores which consisted primarily of structures mimicking GM(2) and GM(3) gangliosides, with minor amounts of structures mimicking GD(1b) and GD(2). Genetic analyses of genes involved in the biosynthesis of the outer core of C. jejuni 81-176 revealed the presence of a homopolymeric tract of G residues within a gene encoding CgtA, an N-acetylgalactosaminyltransferase. Variation in the number of G residues within cgtA affected the length of the open reading frame, and these changes in cgtA corresponded to a change in LOS structure from GM(2) to GM(3) ganglioside mimicry. Site-specific mutation of cgtA in 81-176 resulted in a major LOS core structure that lacked GalNAc and resembled GM(3) ganglioside. Compared to wild-type 81-176, the cgtA mutant showed a significant increase in invasion of INT407 cells. In comparison, a site-specific mutation of the neuC1 gene resulted in the loss of sialic acid in the LOS core and reduced resistance to normal human serum but had no affect on invasion of INT407 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796612      PMCID: PMC127662          DOI: 10.1128/IAI.70.2.787-793.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Lipo-oligosaccharides of Campylobacter jejuni serotype O:10. Structures of core oligosaccharide regions from a bacterial isolate from a patient with the Miller-Fisher syndrome and from the serotype reference strain.

Authors:  J E Shin; S Ackloo; A S Mainkar; M A Monteiro; H Pang; J L Penner; G O Aspinall
Journal:  Carbohydr Res       Date:  1997-12       Impact factor: 2.104

2.  Molecular mimicry in Campylobacter jejuni lipopolysaccharides and the development of Guillain-Barré syndrome.

Authors:  A P Moran; M M Prendergast
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

3.  Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis.

Authors:  U Vogel; A Weinberger; R Frank; A Müller; J Köhl; J P Atkinson; M Frosch
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

4.  The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences.

Authors:  J Parkhill; B W Wren; K Mungall; J M Ketley; C Churcher; D Basham; T Chillingworth; R M Davies; T Feltwell; S Holroyd; K Jagels; A V Karlyshev; S Moule; M J Pallen; C W Penn; M A Quail; M A Rajandream; K M Rutherford; A H van Vliet; S Whitehead; B G Barrell
Journal:  Nature       Date:  2000-02-10       Impact factor: 49.962

5.  Mutation in the peb1A locus of Campylobacter jejuni reduces interactions with epithelial cells and intestinal colonization of mice.

Authors:  Z Pei; C Burucoa; B Grignon; S Baqar; X Z Huang; D J Kopecko; A L Bourgeois; J L Fauchere; M J Blaser
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

6.  Adaptation of Haemophilus influenzae to acquired and innate humoral immunity based on phase variation of lipopolysaccharide.

Authors:  J N Weiser; N Pan
Journal:  Mol Microbiol       Date:  1998-11       Impact factor: 3.501

7.  Biosynthesis of ganglioside mimics in Campylobacter jejuni OH4384. Identification of the glycosyltransferase genes, enzymatic synthesis of model compounds, and characterization of nanomole amounts by 600-mhz (1)h and (13)c NMR analysis.

Authors:  M Gilbert; J R Brisson; M F Karwaski; J Michniewicz; A M Cunningham; Y Wu; N M Young; W W Wakarchuk
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

8.  Campylobacter jejuni 81-176 associates with microtubules and dynein during invasion of human intestinal cells.

Authors:  L Hu; D J Kopecko
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

9.  Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome.

Authors:  G O Aspinall; A G McDonald; H Pang; L A Kurjanczyk; J L Penner
Journal:  Biochemistry       Date:  1994-01-11       Impact factor: 3.162

10.  Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside.

Authors:  M M Prendergast; A J Lastovica; A P Moran
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

View more
  95 in total

Review 1.  Phase and antigenic variation in bacteria.

Authors:  Marjan W van der Woude; Andreas J Bäumler
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

2.  A deep-rough mutant of Campylobacter jejuni 81-176 is noninvasive for intestinal epithelial cells.

Authors:  Margaret I Kanipes; Lindsay C Holder; Adrian T Corcoran; Anthony P Moran; Patricia Guerry
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

3.  Campylobacter jejuni translocation across intestinal epithelial cells is facilitated by ganglioside-like lipooligosaccharide structures.

Authors:  Rogier Louwen; Edward E S Nieuwenhuis; Leonie van Marrewijk; Deborah Horst-Kreft; Lilian de Ruiter; Astrid P Heikema; Willem J B van Wamel; Jaap A Wagenaar; Hubert P Endtz; Janneke Samsom; Peter van Baarlen; Anna Akhmanova; Alex van Belkum
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

4.  Structural and functional divergence of MutS2 from bacterial MutS1 and eukaryotic MSH4-MSH5 homologs.

Authors:  Josephine Kang; Shuyan Huang; Martin J Blaser
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

5.  The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome.

Authors:  Peggy C R Godschalk; Astrid P Heikema; Michel Gilbert; Tomoko Komagamine; C Wim Ang; Jobine Glerum; Denis Brochu; Jianjun Li; Nobuhiro Yuki; Bart C Jacobs; Alex van Belkum; Hubert P Endtz
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

6.  Campylobacter jejuni biofilms up-regulated in the absence of the stringent response utilize a calcofluor white-reactive polysaccharide.

Authors:  Meghan K McLennan; Danielle D Ringoir; Emilisa Frirdich; Sarah L Svensson; Derek H Wells; Harold Jarrell; Christine M Szymanski; Erin C Gaynor
Journal:  J Bacteriol       Date:  2007-11-09       Impact factor: 3.490

7.  Murine Models for the Investigation of Colonization Resistance and Innate Immune Responses in Campylobacter Jejuni Infections.

Authors:  Soraya Mousavi; Stefan Bereswill; Markus M Heimesaat
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

8.  Selective biochemical labeling of Campylobacter jejuni cell-surface glycoconjugates.

Authors:  Garrett E Whitworth; Barbara Imperiali
Journal:  Glycobiology       Date:  2015-03-11       Impact factor: 4.313

9.  The polysaccharide capsule of Campylobacter jejuni modulates the host immune response.

Authors:  Alexander C Maue; Krystle L Mohawk; David K Giles; Frédéric Poly; Cheryl P Ewing; Yuening Jiao; Ginyoung Lee; Zuchao Ma; Mario A Monteiro; Christina L Hill; Jason S Ferderber; Chad K Porter; M Stephen Trent; Patricia Guerry
Journal:  Infect Immun       Date:  2012-12-17       Impact factor: 3.441

10.  Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

Authors:  David R Tribble; Shahida Baqar; Daniel A Scott; Michael L Oplinger; Fernando Trespalacios; David Rollins; Richard I Walker; John D Clements; Steven Walz; Paul Gibbs; Edward F Burg; Anthony P Moran; Lisa Applebee; A Louis Bourgeois
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.